49.56
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Avidity reports positive pre-BLA meeting on Duchenne muscular dystrophy asset del-zota - Seeking Alpha
Sector ETF performance correlation with Avidity Biosciences Inc.Market Performance Report & Verified Momentum Watchlists - newser.com
Avidity rises on plans to submit muscle wasting drug application to US FDA - TradingView
Avidity Biosciences Completes FDA Pre-BLA Meeting for Del-Zota, Targets 2026 Submission - MarketScreener
Avidity Biosciences delays DMD drug submission to Q1 2026 - Investing.com India
Can Avidity Biosciences Inc. stock beat market expectations this quarterMarket Growth Review & Verified Technical Trade Signals - newser.com
Q1 2026 BLA Planned: Avidity's Breakthrough Therapy del‑zota Receives Positive FDA Pre‑BLA Guidance - Stock Titan
Will a bounce in Avidity Biosciences Inc. offer an exitWeekly Trend Summary & Real-Time Stock Price Movement Reports - newser.com
How Avidity Biosciences Inc. stock compares to growth peersQuarterly Profit Review & Safe Entry Trade Reports - newser.com
Forecasting Avidity Biosciences Inc. price range with options dataWeekly Trade Analysis & Verified Momentum Stock Alerts - newser.com
What Makes Avidity Biosciences (RNA) an Investment Choice? - Yahoo Finance
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring a 36.85% Potential Upside in Innovative RNA Therapeutics - DirectorsTalk Interviews
Using R and stats models for Avidity Biosciences Inc. forecastingIndex Update & Community Shared Stock Ideas - newser.com
Chart based exit strategy for Avidity Biosciences Inc.Market Growth Review & Low Risk Entry Point Tips - newser.com
Avidity Biosciences Inc. stock daily chart insightsGap Down & Weekly Top Performers Watchlists - newser.com
Can Avidity Biosciences Inc. stock hit record highs againPortfolio Value Report & Low Risk High Win Rate Stock Picks - newser.com
Avidity Biosciences (NASDAQ:RNA) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Ranking Avidity Biosciences Inc. among high performing stocks via toolsWeekly Stock Recap & Weekly High Momentum Picks - newser.com
Is Avidity Biosciences Inc a good long term investmentMid Cap Growth Trends & Low Entry Capital Stocks - earlytimes.in
What drives Ball Corporation stock priceBlue Chip Stock Analysis & High Return Trading Portfolio - earlytimes.in
Avidity Biosciences’ Phase 2 Study on AOC 1001: A Potential Game-Changer for DM1 Treatment - TipRanks
Avidity Biosciences (NASDAQ:RNA) Insider Eric Mosbrooker Sells 6,562 Shares - MarketBeat
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society - Sahm
Avidity Biosciences (RNA): Assessing Valuation Following Recent Positive Share Price Momentum - Yahoo Finance
Avidity Poised For Commercialization Transformation - San Diego Business Journal
Quantitative breakdown of Avidity Biosciences Inc. recent move2025 Growth vs Value & Safe Entry Momentum Stock Tips - newser.com
Avidity Biosciences Inc. stock trendline breakdownPortfolio Value Report & Free Weekly Watchlist of Top Performers - newser.com
Avidity Biosciences Inc Stock Analysis and ForecastStock Price Targets & 5 Stocks Every Investor Should Own - earlytimes.in
Combining machine learning predictions for Avidity Biosciences Inc.Buy Signal & Fast Moving Stock Watchlists - newser.com
Relative strength of Avidity Biosciences Inc. in sector analysisJuly 2025 Action & High Accuracy Trade Signal Alerts - newser.com
Avidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Avidity Biosciences Stock Price, Quotes and Forecasts | NASDAQ:RNA - Benzinga
BofA Securities Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $65 - 富途牛牛
Can Avidity Biosciences Inc. hit a new high this monthEarnings Summary Report & Weekly Market Pulse Updates - newser.com
Real time scanner hits for Avidity Biosciences Inc. explainedBull Run & Technical Entry and Exit Alerts - newser.com
Is Avidity Biosciences Inc. building a consolidation baseJuly 2025 Catalysts & Weekly Breakout Stock Alerts - newser.com
Avidity Biosciences Prices $600 Million Upsized Public Offering of Common Stock - Global Legal Chronicle
Avidity Biosciences Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Avidity Biosciences (NASDAQ:RNA) Shares Down 7.6%Here's What Happened - MarketBeat
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):